Aktis Oncology AKTS

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Drug Manufacturers - General nearest Aktis Oncology's size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
AKTSAktis Oncology	$874.9M	n/m	n/a		n/m	n/m	n/m
ABUSArbutus Biopharma	$831M	5.4×	5.6×		4.6×	n/m	84.2%
COLLCollegium Pharmaceutical	$747.5M	18.5×	19.1×		0.9×	+14%	5.9%
AMPHAmphastar Pharmaceuticals	$1.1B	14.8×	20.6×		1.5×	+1%	10.8%
OMEROmeros	$1.2B	10.9×	11.7×		n/m	n/m	n/m
CRMDCorMedix	$611.9M	3.7×	4.0×		1.3×	+281%	40.5%
ZVRAZevra Therapeutics	$582.6M	10.5×	12.3×		4.3×	+119%	42.8%
IRWDIronwood Pharmaceuticals	$571.7M	4.5×	14.9×		1.5×	+26%	33.4%
PBYIPuma Biotechnology	$568.9M	21.2×	12.3×		2.5×	−3%	11.6%
PCRXPacira BioSciences	$1.5B	104×	65.6×		1.9×	+6%	2.0%
ANABAnaptysbio	$1.5B	10.7×	100.0×		n/m	n/m	n/m
Peer median	$789.2M	10.8×	13.6×		1.7×	+14%	22.5%

Investors we follow who held Aktis Oncology at the end of Jun 30, 2026, from their 13F filings.

• Polen CapitalPolen Capital0.0% of portfolionew

Each number over time

• Revenue
• EPS
• Free cash flow
• Shares outstanding

Its groups

• Drug Manufacturers - General
• Healthcare

Industry

Drug Manufacturers - General

Sector

Healthcare